327 related articles for article (PubMed ID: 26896194)
1. Donor-Specific HLA Antibodies in Living Versus Deceased Donor Liver Transplant Recipients.
Levitsky J; Kaneku H; Jie C; Walsh RC; Abecassis M; Tambur AR
Am J Transplant; 2016 Aug; 16(8):2437-44. PubMed ID: 26896194
[TBL] [Abstract][Full Text] [Related]
2. Preformed donor-specific antibodies do not affect the 1-year allograft survival in living donor liver transplantation.
Kim H; Yi NJ; Song EY; Lee K; Lee KW; Lee HW; Ahn HY; Yoon KC; Hong SK; Suh KS
Clin Transplant; 2018 May; 32(5):e13244. PubMed ID: 29577436
[TBL] [Abstract][Full Text] [Related]
3. Incidences of preformed and de novo donor-specific HLA antibodies and their clinicohistological correlates in the early course of kidney transplantation.
Huang Y; Ramon D; Luan FL; Sung R; Samaniego M
Clin Transpl; 2012; ():247-56. PubMed ID: 23721029
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
[TBL] [Abstract][Full Text] [Related]
5. Incidence and severity of acute cellular rejection in recipients undergoing adult living donor or deceased donor liver transplantation.
Shaked A; Ghobrial RM; Merion RM; Shearon TH; Emond JC; Fair JH; Fisher RA; Kulik LM; Pruett TL; Terrault NA;
Am J Transplant; 2009 Feb; 9(2):301-8. PubMed ID: 19120082
[TBL] [Abstract][Full Text] [Related]
6. Preformed Donor-Specific HLA Antibodies in Living and Deceased Donor Transplantation: A Multicenter Study.
Ziemann M; Altermann W; Angert K; Arns W; Bachmann A; Bakchoul T; Banas B; von Borstel A; Budde K; Ditt V; Einecke G; Eisenberger U; Feldkamp T; Görg S; Guthoff M; Habicht A; Hallensleben M; Heinemann FM; Hessler N; Hugo C; Kaufmann M; Kauke T; Koch M; König IR; Kurschat C; Lehmann C; Marget M; Mühlfeld A; Nitschke M; Pego da Silva L; Quick C; Rahmel A; Rath T; Reinke P; Renders L; Sommer F; Spriewald B; Staeck O; Stippel D; Süsal C; Thiele B; Zecher D; Lachmann N
Clin J Am Soc Nephrol; 2019 Jul; 14(7):1056-1066. PubMed ID: 31213508
[TBL] [Abstract][Full Text] [Related]
7. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients.
Kaneku H; O'Leary JG; Banuelos N; Jennings LW; Susskind BM; Klintmalm GB; Terasaki PI
Am J Transplant; 2013 Jun; 13(6):1541-8. PubMed ID: 23721554
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of donor-specific HLA antibodies in living versus deceased donor transplant.
Kamburova EG; Wisse BW; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; Spierings E; Hack CE; van Reekum FE; van Zuilen AD; Verhaar MC; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JSF; Hepkema BG; Lambeck AJA; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens M; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KA; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma A; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG
Am J Transplant; 2018 Sep; 18(9):2274-2284. PubMed ID: 29464832
[TBL] [Abstract][Full Text] [Related]
9. Preformed and de novo donor specific antibodies in visceral transplantation: long-term outcome with special reference to the liver.
Abu-Elmagd KM; Wu G; Costa G; Lunz J; Martin L; Koritsky DA; Murase N; Irish W; Zeevi A
Am J Transplant; 2012 Nov; 12(11):3047-60. PubMed ID: 22947059
[TBL] [Abstract][Full Text] [Related]
10. Immunologic benefits of maternal living donor allografts in pediatric liver transplantation: fewer rejection episodes and no evidence of de novo allosensitization.
Barbetta A; Meeberg G; Rocque B; Barhouma S; Weaver C; Gilmour S; Faytrouni F; Guttman O; Zielsdorf S; Etesami K; Kwon Y; Yanni G; Campbell P; Shapiro J; Emamaullee J
Pediatr Transplant; 2022 May; 26(3):e14197. PubMed ID: 34806273
[TBL] [Abstract][Full Text] [Related]
11. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
Jalalonmuhali M; Carroll RP; Tsiopelas E; Clayton P; Coates PT
Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243
[TBL] [Abstract][Full Text] [Related]
12. De Novo Donor-Specific HLA Antibodies Are Associated With Rapid Loss of Graft Function Following Islet Transplantation in Type 1 Diabetes.
Brooks AM; Carter V; Liew A; Marshall H; Aldibbiat A; Sheerin NS; Manas DM; White SA; Shaw JA
Am J Transplant; 2015 Dec; 15(12):3239-46. PubMed ID: 26227015
[TBL] [Abstract][Full Text] [Related]
13. Complications and Their Resolution in Recipients of Deceased and Living Donor Liver Transplants: Findings From the A2ALL Cohort Study.
Samstein B; Smith AR; Freise CE; Zimmerman MA; Baker T; Olthoff KM; Fisher RA; Merion RM
Am J Transplant; 2016 Feb; 16(2):594-602. PubMed ID: 26461803
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant Recipients.
Cheng EY; Everly MJ; Kaneku H; Banuelos N; Wozniak LJ; Venick RS; Marcus EA; McDiarmid SV; Busuttil RW; Terasaki PI; Farmer DG
Transplantation; 2017 Apr; 101(4):873-882. PubMed ID: 27490417
[TBL] [Abstract][Full Text] [Related]
15. Preformed and de novo DSA are associated with T-cell-mediated rejection in pediatric liver transplant recipients requiring clinically indicated liver biopsy.
Schluckebier D; Cousin VL; Petit LM; Belli D; Wildhaber B; Rougemont AL; Villard J; Ferrari-Lacraz S; McLin VA
Pediatr Transplant; 2020 Feb; 24(1):e13611. PubMed ID: 31682057
[TBL] [Abstract][Full Text] [Related]
16. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation.
Terrault NA; Shiffman ML; Lok AS; Saab S; Tong L; Brown RS; Everson GT; Reddy KR; Fair JH; Kulik LM; Pruett TL; Seeff LB;
Liver Transpl; 2007 Jan; 13(1):122-9. PubMed ID: 17192908
[TBL] [Abstract][Full Text] [Related]
17. Adult Living Donor Versus Deceased Donor Liver Transplant (LDLT Versus DDLT) at a Single Center: Time to Change Our Paradigm for Liver Transplant.
Humar A; Ganesh S; Jorgensen D; Tevar A; Ganoza A; Molinari M; Hughes C
Ann Surg; 2019 Sep; 270(3):444-451. PubMed ID: 31305283
[TBL] [Abstract][Full Text] [Related]
18. Preformed donor-specific HLA antibodies are associated with increased risk of early mortality after liver transplantation.
McCaughan JA; Robertson V; Falconer SJ; Cryer C; Turner DM; Oniscu GC
Clin Transplant; 2016 Dec; 30(12):1538-1544. PubMed ID: 27653177
[TBL] [Abstract][Full Text] [Related]
19. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies.
Cuevas E; Arreola-Guerra JM; Hernández-Méndez EA; Salcedo I; Castelán N; Uribe-Uribe NO; Vilatobá M; Contreras-Saldívar AG; Sánchez-Cedillo AI; Ramírez JB; de Rungs D; Granados J; Morales-Buenrostro LE; Alberú J
Nephrol Dial Transplant; 2016 Oct; 31(10):1738-45. PubMed ID: 27220757
[TBL] [Abstract][Full Text] [Related]
20. Use of living donor liver transplantation varies with the availability of deceased donor liver transplantation.
Vagefi PA; Ascher NL; Freise CE; Dodge JL; Roberts JP
Liver Transpl; 2012 Feb; 18(2):160-5. PubMed ID: 22006378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
